Prognostic value of systemic inflammation‐based markers in advanced pancreatic cancer

Martin, Helen Eastman; Ohara, Kiyoshi; Kiberu, Andrew Ddembe; Hagen, Tom van; Davidson, Andrew R.; Khattak, Muhammad A.

doi:10.1111/imj.12453

Cited by 109 publications

(110 citation statements)

References 38 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…The clinical utility of new diagnostic markers of malignancies must be evaluated to identify potentially useful methods for prognosis and treatment monitoring. In recent years, accumulating evidence has elucidated the role of inflammation-based prognostic scores, including PNI, NLR, PLR, PI, mGPS and GPS in cancer patient prognosis (12)(13)(14)(15). Although several studies have identified CAR as a prognostic factor for patients with various types of tumors (6)(7)(8), the prognostic value in patients with ESCC remained unclear (16).…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of the C‑reactive protein‑to‑albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical significance of the C‑reactive protein‑to‑albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

“…(7,(20)(21)(22). It was reported that the N/L ratio was a poor prognostic factor in non-small cell lung cancer, acute-on-chronic hepatitis B liver failure, advanced pancreatic cancer, and biliary tract cancer (12)(13)(14)23). In patients with idiopathic dilated cardiomyopathy, the N/L ratio is associated with the severity of chronic heart failure (22).…”

Section: Discussionmentioning

confidence: 99%

“…White blood cell (WBC) counts, neutrophil counts, lymphocyte counts, age, sex, and mutation types of patients were extracted. The N/L ratio was calculated by dividing the absolute neutrophil counts with the absolute lymphocyte counts, obtained from the differential WBC count (12)(13)(14)(15)(16)(17).…”

Section: Methodsmentioning

confidence: 99%

“…It was shown that inflammation continues not only during attacks but also during symptom-free periods (8)(9)(10)(11). The neutrophil/lymphocyte (N/L) ratio can be easily obtained from the differential white blood cell (WBC) count and has been studied in the context of many diseases (12)(13)(14)(15)(16)(17). It is a marker of inflammation and predicts disease prognosis (7,15).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neutrophil-lymphocyte ratio in children with familial Mediterranean fever: original article

Duksal¹,

Alaygut²,

Güven³

et al. 2015

Eur J Rheumatol

View full text Add to dashboard Cite

Objective: The aim of present study was (a) to evaluate the relationship between the neutrophil/lymphocyte (N/L) ratio and mutation types of familial Mediterranean fever (FMF) in children and (b) to evaluate the relationship between the N/L ratio and age.Material and Methods: Three hundred forty-three children with familial Mediterranean fever in the attack-free period and 283 healthy control children were included in the study. Patients were divided into subgroups according to mutation types. Neutrophil and lymphocyte counts were retrieved from medical records of patients and the N/L ratio was calculated from these parameters. Results:The N/L ratio of patients was found to be significantly higher than that of controls (p<0.001). Among 343 patients, homozygous, heterozygous, and compound mutations were observed in 39, 253, and 51 patients, respectively. The differences in the N/L ratio among patients with homozygous, heterozygous, and compound mutations were not statistically significant. The most common mutations were M694V (n=126), E148Q (n=70), M680I, (n=33), and V726A (n=28). Significant differences were not observed among these mutations in terms of the N/L ratio (p>0.05). In all subjects, there was a weak but significant relationship between age and the N/L ratio (r: 0.215, p<0.001). Conclusion:The N/L ratio, which can be determined by simple methods in routine blood tests, may be used for the follow-up monitoring of chronic inflammation in patients. In addition, the N/L ratio may give an idea to clinicians regarding the early initiation of treatment in patients with typical clinical findings of FMF.

show abstract

“…Among various immunological processes, neutrophils and lymphocytes are reported to have a vital role in tumor inflammation and immunology. It has been demonstrated that the peripheral blood neutrophil-to-lymphocyte ratio (NLR), or more recently the derived NLR (dNLR), may be a reliable prognostic marker in various types of cancer, including PDAC (12)(13)(14)(15)(16)(17)(18), However, the use of the dNLR in predicting susceptibility to chemotherapy has not been evaluated. Therefore, the present study aimed to evaluate whether the dNLR is a reliable predictive marker for gemcitabine response in patients with unresectable PDAC.…”

Section: Introductionmentioning

confidence: 99%

Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer

et al. 2016

View full text Add to dashboard Cite

Abstract.As gemcitabine is a key anti-tumor agent for unresectable pancreatic ductal adenocarcinoma (PDAC), it is important to predict the outcomes of gemcitabine chemotherapy. The present study aimed to confirm whether the derived neutrophil-to-lymphocyte ratio (dNLR) is able to predict chemotherapy outcomes. To elucidate the role of dNLR in patients that underwent chemotherapy, the current study evaluated clinicopathological variables in 31 patients with unresectable PDAC treated with gemcitabine. The correlation between clinicopathological variables, and progression-free survival (PFS) and overall survival (OS) time were investigated. Univariate analysis revealed that there were no significant differences in PFS and OS as a function of age (<65 vs. ≥65 years), gender, tumor location (pancreas head vs. body/tail), tumor diameter (<23 vs. ≥23 mm) or serum carbohydrate antigen 19-9 concentration level (<3,800 vs. ≥3,800 U/ml). However, disease stage (locally advanced vs. metastatic) and the dNLR (<2.5 vs. ≥2.5) significantly affected PFS and OS. Multivariate analysis subsequently revealed that a dNLR of ≥2.5 was an independent prognostic factor for poor PFS (P=0.003) and OS (P=0.026). In conclusion, data from the present study suggests that the pre-treatment dNLR is an independent prognostic factor to predict PFS and OS in patients with unresectable PDAC treated with gemcitabine. This indicates that dNLR has a potential role in stratifying patients that may benefit from gemcitabine therapy.

show abstract

Prognostic value of systemic inflammation‐based markers in advanced pancreatic cancer

Abstract: Our findings suggest that the NLR, PLR and mGPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.

Cited by 109 publications

References 38 publications

Clinical significance of the C‑reactive protein‑to‑albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma

Clinical significance of the C‑reactive protein‑to‑albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma

Neutrophil-lymphocyte ratio in children with familial Mediterranean fever: original article

Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer

Contact Info

Product

Resources

About